Skip to content

Novel Pharmacotherapy for Dual Dependence

Novel Pharmacotherapy for Dual Dependence

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00448825
Enrollment
180
Registered
2007-03-19
Start date
2007-03-31
Completion date
2013-06-30
Last updated
2013-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Dependence, Cocaine Dependence

Keywords

alcohol dependence, alcoholism, cocaine addiction, cocaine dependence

Brief summary

The purpose of this study is to evaluate the effects of Topiramate and Cognitive Behavioral Therapy for the treatment of alcohol and cocaine dependence.

Detailed description

Our objective is to understand the basic mechanisms that underpin substance dependence, and to develop efficacious treatments for individuals with comorbid cocaine and alcohol dependence. Participants in this study will be randomly assigned to receive either 300 mg per day of topiramate or placebo. In addition, participants will receive weekly cognitive behavioral therapy for 12 weeks.Follow-up visits will occur at 2 weeks and 1,2,, and 3 months following completion of treatment.

Interventions

Topiramate up to 300 mg per day

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Bankole Johnson
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects will be men and women between the ages of 18 years and older. * Must meet at least three of the seven DSM IV diagnostic criteria for alcohol and cocaine dependence. * Express a desire for treatment. * Literacy in English and ability to read, understand, and complete the ratings scales and questionnaires accurately, follow instructions, and make use of the behavioral treatments are required. * Prospective subjects must report cocaine use of at least once per month and alcohol consumption of ≥21 drinks/week and ≥14 drinks/week for men and women respectively, during the past 30 days * At least one positive urine drug screen for cocaine at screen or baseline prior to randomization.

Exclusion criteria

Please contact site for additional information

Design outcomes

Primary

MeasureTime frameDescription
The topiramate group will be superior to the placebo group on the following outcome measures:increasing the weekly mean proportion of cocaine-free days, decreasing self-reported drinking, and decreasing craving for cocaine and alcohol.According to Preston Rules from weeks 6 to 12.Alcohol - assessed by self-report of use (TLFB,DD,DDD,PDA, PHDD), biochemical markers (GGT, CDT), OCDS Cocaine - assessed by self-report of use (CTFB, substance use inventory, QFI),urine assay for benzoylecgonine, and CCQ-NOW

Secondary

MeasureTime frameDescription
a. Cocaine free weeks; b. Topiramate, compared with placebo, will be associated with an improvement in psychosocial functioning as exemplified by improved general well-being, social functioning, and quality of life.According to Preston Rules from weeks 1 to 121. Cocaine free weeks is assessed by a combination of self-report of use and urine assays; 2. Assessed by increased scores in the following assessments: CGI, BSI, Q-LES-Q, DrInC, SFQ, medication compliance, CIWA-Ar, POMS, BIS

Countries

United States

Contacts

Primary ContactMindy Borszich
mcb3x@virginia.edu1-888-882-2345
Backup ContactEva Jenkins-Mendoza
emj9c@virginia.edu(434)243-0562

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026